Poehling Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $703K | Sell |
2,793
-14
| -0.5% | -$3.01K | 0.15% | 98 |
|
|
2026
Q1 | $610K | Sell |
2,807
-33
| -1% | -$7.32K | 0.13% | 97 |
|
|
2025
Q4 | $649K | Sell |
2,840
-1,240
| -30% | -$282K | 0.13% | 89 |
|
|
2025
Q3 | $945K | Buy |
4,080
+12
| +0.3% | +$2.44K | 0.2% | 81 |
|
|
2025
Q2 | $755K | Buy |
4,068
+50
| +1% | +$9.29K | 0.18% | 80 |
|
|
2025
Q1 | $842K | Sell |
4,018
-127
| -3% | -$24.7K | 0.21% | 80 |
|
|
2024
Q4 | $737K | Sell |
4,145
-34
| -0.8% | -$6.25K | 0.18% | 84 |
|
|
2024
Q3 | $825K | Sell |
4,179
-28
| -0.7% | -$5.23K | 0.21% | 79 |
|
|
2024
Q2 | $722K | Sell |
4,207
-9,058
| -68% | -$1.5M | 0.2% | 81 |
|
|
2024
Q1 | $2.42M | Sell |
13,265
-387
| -3% | -$66.7K | 0.65% | 49 |
|
|
2023
Q4 | $2.12M | Sell |
13,652
-3,815
| -22% | -$556K | 0.67% | 52 |
|
|
2023
Q3 | $2.6M | Buy |
17,467
+227
| +1% | +$33.3K | 0.91% | 33 |
|
|
2023
Q2 | $2.32M | Sell |
17,240
-23,368
| -58% | -$3.43M | 0.78% | 41 |
|
|
2023
Q1 | $6.47M | Sell |
40,608
-625
| -2% | -$95.6K | 2.18% | 10 |
|
|
2022
Q4 | $6.66M | Buy |
41,233
+510
| +1% | +$78.2K | 2.5% | 7 |
|
|
2022
Q3 | $5.46M | Sell |
40,723
-282
| -0.7% | -$40.5K | 2.29% | 16 |
|
|
2022
Q2 | $6.28M | Sell |
41,005
-975
| -2% | -$149K | 2.36% | 14 |
|
|
2022
Q1 | $6.8M | Sell |
41,980
-437
| -1% | -$63.5K | 2.1% | 12 |
|
|
2021
Q4 | $5.74M | Sell |
42,417
-653
| -2% | -$77.1K | 1.85% | 14 |
|
|
2021
Q3 | $4.65M | Buy |
43,070
+3,641
| +9% | +$416K | 1.57% | 18 |
|
|
2021
Q2 | $4.44M | Buy |
39,429
+263
| +0.7% | +$29.6K | 1.41% | 19 |
|
|
2021
Q1 | $4.24M | Buy |
39,166
+3,038
| +8% | +$325K | 1.48% | 16 |
|
|
2020
Q4 | $3.87M | Buy |
36,128
+55
| +0.2% | +$5.29K | 1.54% | 17 |
|
|
2020
Q3 | $3.16M | Buy |
36,073
+618
| +2% | +$58.2K | 1.62% | 15 |
|
|
2020
Q2 | $3.48M | Buy |
35,455
+220
| +0.6% | +$19.4K | 1.87% | 12 |
|
|
2020
Q1 | $2.69M | Buy |
35,235
+10,695
| +44% | +$911K | 1.97% | 12 |
|
|
2019
Q4 | $2.17M | Buy |
24,540
+525
| +2% | +$43.6K | 1.42% | 20 |
|
|
2019
Q3 | $1.82M | Buy |
24,015
+9,309
| +63% | +$638K | 1.33% | 23 |
|
|
2019
Q2 | $1.07M | Buy |
14,706
+840
| +6% | +$66K | 0.72% | 47 |
|
|
2019
Q1 | $1.12M | Buy |
13,866
+210
| +2% | +$17.2K | 0.81% | 48 |
|
|
2018
Q4 | $1.26M | Buy |
13,656
+5,391
| +65% | +$474K | 1.21% | 24 |
|
|
2018
Q3 | $782K | Buy |
8,265
+3,840
| +87% | +$364K | 0.55% | 53 |
|
|
2018
Q2 | $410K | Sell |
4,425
-3,815
| -46% | -$373K | 0.36% | 69 |
|
|
2018
Q1 | $780K | Hold |
8,240
| – | – | 0.63% | 50 |
|
|
2017
Q4 | $797K | Buy |
+8,240
| New | +$777K | 0.68% | 49 |
|
Other funds holding ABBV
LMFP
ATO
HCM
AAMU
FWCM
Poehling Capital Management's ABBV Position: Q2 2026 in Review
Poehling Capital Management reduced its AbbVie (ABBV) stake by 0.5% in Q2 2026, selling an estimated $3.01K and leaving 2,793 shares worth $703K. The position accounts for 0.15% of the portfolio, ranked #98.
Poehling Capital Management first reported a position in ABBV in Q4 2017 and has held it in 35 quarters since. The position peaked at $6.8M in Q1 2022. 1,476 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Poehling Capital Management held 2,793 shares of AbbVie worth $703K as of Q2 2026.
- Poehling Capital Management sold 14 AbbVie shares in Q2 2026, an estimated $3.01K.
- AbbVie made up 0.15% of Poehling Capital Management's portfolio in Q2 2026, its #98 holding.
- Poehling Capital Management first reported a position in AbbVie in Q4 2017 and has held it in 35 quarters since.
- Poehling Capital Management's AbbVie position peaked at $6.8M in Q1 2022.
- 1,476 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Poehling Capital Management's 13F filing for Q2 2026, filed 20 Jul 2026.